Diabetes (type 2) - glitazones (replaced by CG66)
Glitazones in the treatment of type 2 diabetes (Review of TA9 and TA21)
Summary
The recommendations in this technology appraisal have been replaced by recommendations in the type 2 diabetes clinical guideline published in May 2008. Therefore this guidance is obsolete.
Guidance documents
Implementing this guidance
Other information
About this guidance
Technology appraisals TA63
Issued: August 2003
How this guidance was produced